Patents by Inventor Dan V. Mourich

Dan V. Mourich has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7989608
    Abstract: An antisense oligonucleotide compound, composition, vaccine and methods for treating a variety of conditions characterized by up-regulation of IL-10 in a mammalian subject are disclosed. The compound (i) is composed of morpholino subunits and phosphorus-containing intersubunit linkages joining a morpholino nitrogen of one subunit to a 5? exocyclic carbon of an adjacent subunit, (ii) is capable of uptake by monocytes, lymphocytes, and dendritic cells in a mammalian subject, (iii) contains between 10-40 nucleotide bases, and (iv) has a base sequence effective to hybridize to at least 12 contiguous bases of a target sequence contained in an exon-2 or exon-4 slice site region of human IL-10 pre-mRNA.
    Type: Grant
    Filed: December 24, 2008
    Date of Patent: August 2, 2011
    Assignee: AVI BioPharma Inc.
    Inventors: Dan V. Mourich, Patrick L. Iversen
  • Publication number: 20100184670
    Abstract: Provided are methods and compositions, including topical compositions, for inducing tolerance to a sensitizing agent known to provoke contact hypersensitivity in a subject. Included are methods of topically applying to the subject an effective amount of an antisense composition targeting the start site or splice site of a CFLAR mRNA.
    Type: Application
    Filed: December 17, 2009
    Publication date: July 22, 2010
    Inventors: Dan V. Mourich, Nikki B. Marshall, Patrick L. Iversen
  • Publication number: 20090246221
    Abstract: An antisense oligonucleotide compound, composition, vaccine and methods for treating a variety of conditions characterized by up-regulation of IL-10 in a mammalian subject are disclosed. The compound (i) is composed of morpholino subunits and phosphorus-containing intersubunit linkages joining a morpholino nitrogen of one subunit to a 5? exocyclic carbon of an adjacent subunit, (ii) is capable of uptake by monocytes, lymphocytes, and dendritic cells in a mammalian subject, (iii) contains between 10-40 nucleotide bases, and (iv) has a base sequence effective to hybridize to at least 12 contiguous bases of a target sequence contained in an exon-2 or exon-4 slice site region of human IL-10 pre-mRNA.
    Type: Application
    Filed: December 24, 2008
    Publication date: October 1, 2009
    Applicant: AVI BioPharma, Inc.
    Inventors: Dan V. Mourich, Patrick L. Iversen
  • Publication number: 20090111977
    Abstract: A method and conjugate for selectively killing antigen-activated T cells are disclosed. The conjugate is composed of a substantially uncharged antisense compound targeted against the human cFLIP protein, and a reverse TAT (rTAT) polypeptide coupled covalently to the antisense compound. The rTAT polypeptide is effective to produce selective uptake of the conjugate into antigen-activated T cells, relative to the uptake of the conjugate into non-activated T cells. The cFLIP antisense compound causes activation induced cell death (AICD) of activated lymphocytes. The method is useful in treating transplantation rejection and autoimmune conditions.
    Type: Application
    Filed: November 15, 2007
    Publication date: April 30, 2009
    Applicant: AVI BioPharma, Inc.
    Inventors: Dan V. Mourich, Hong Mu Moulton, David J. Hinrichs, Patrick L. Iversen
  • Publication number: 20090110689
    Abstract: A method and compound for suppressing an immune response in a mammalian subject, for the treatment or prevention of an autoimmune condition or transplantation rejection are disclosed. The compound is an antisense oligonucleotide analog compound having a targeting sequence complementary to a preprocessed CTLA-4 mRNA region identified by SEQ ID NO: 22 in SEQ ID NO: 1, spanning the splice junction between intron 1 and exon 2 of the preprocessed mRNA of the subject. The compound is effective, when administered to a subject, to form within host cells, a heteroduplex structure (i) composed of the preprocessed CTLA-4 mRNA and the oligonucleotide compound, (ii) characterized by a Tm of dissociation of at least 45° C., and (iii) resulting in an increased ratio of processed mRNA encoding ligand-independent CTLA-4 to processed mRNA encoding full-length CTLA-4.
    Type: Application
    Filed: November 7, 2008
    Publication date: April 30, 2009
    Applicant: AVI BIOPHARMA, INC.
    Inventors: DAN V. MOURICH, PATRICK L. IVERSEN, DWIGHT D. WELLER
  • Publication number: 20080187993
    Abstract: A method and conjugate for selectively targeting activated hematopoietic cells, e.g., macrophage or T-lymphocyte cells, are disclosed. The conjugate is composed of a substantially uncharged antisense compound targeted against HIV, and a reverse TAT (rTAT) polypeptide coupled covalently to the antisense compound. The rTAT polypeptide is effective to produce selective uptake of the conjugate into activated, HIV-infected cells, e.g., activated, HIV-infected macrophage and T-lymphocyte cells. An exemplary embodiment of the invention provides an antisense compound directed to the HIV Vif gene, causing the production of defective HIV virions in an infected individual.
    Type: Application
    Filed: November 15, 2007
    Publication date: August 7, 2008
    Applicant: AVI BioPharma, Inc.
    Inventors: Dan V. Mourich, Patrick L. Iversen, Richard K. Bestwick